top of page
METABOLIC ENHANCERS FOR CELL THERAPIES
Unique reagents. Novel pathways. Easy to integrate.
Boosts fitness
Extends persistence
Accelerates expansion
Backed by peer-reviewed in vivo data demonstrating improved tumor control.
Consistently generate stem cell memory T cells to unlock more durable CAR-T therapies.
Accelerates CAR-T expansion, shortening production timelines and lowering cost per dose.
News
Commercial launch of MitoStem™, our first ex vivo reagent designed to enhance cell therapy performance by increasing durable, stem-like T cell populations.
Oct 2025 - Best European Healthcare Startup Award
Recognized at HWL Luxembourg for our pioneering work in mitochondrial reprogramming and its therapeutic potential across multiple disease areas.
Feb 2025 - Landmark publication validates mitochondrial reprogramming approach
​MPC Therapeutics’ research published in Molecular Therapy: Oncology demonstrates that MITO-66 enhances CAR T cell persistence and antitumor efficacy by inducing a stem cell-like memory phenotype.
bottom of page